No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
CAPR Capricor Therapeutics
- 5.170
- -0.120-2.27%
Close Jun 14 16:00 ET
- 5.030
- -0.140-2.71%
Post 18:15 ET
164.47MMarket Cap-6228P/E (TTM)
5.349High5.030Low218.60KVolume5.250Open5.290Pre Close1.12MTurnover0.83%Turnover RatioLossP/E (Static)31.81MShares8.22152wk High8.91P/B136.43MFloat Cap2.68052wk Low--Dividend TTM26.39MShs Float7999.998Historical High--Div YieldTTM6.03%Amplitude0.880Historical Low5.127Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | Capricor Therapeutics Files For Mixed Shelf Offering Of Up To $150M
Express News | Capricor Therapeutics Inc Files for Mixed Shelf Offering of up to $150 Mln- SEC Filing
12 Health Care Stocks Moving In Tuesday's After-Market Session
GainersAutonomix Medical (NASDAQ:AMIX) shares moved upwards by 11.1% to $1.3 during Tuesday's after-market session. The company's market cap stands at $24.4 million. Unicycive Therapeutics (NASDAQ:UNC
Sector Update: Health Care Stocks Decline Tuesday Afternoon
Health care stocks were lower Tuesday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) each shedding about 0.6%. The iShares Biotechnology ETF (IBB) fell ab
Capricor Says FDA Grants Pre-BLA Meeting Request for Duchenne Muscular Dystrophy Treatment; Shares Rise
Capricor Therapeutics (CAPR) said Tuesday the US Food and Drug Administration has agreed to a pre-biologics license application meeting regarding the company's lead CAP-1002 treatment candidate for Du
Express News | Capricor Anticipates Hope-3 Trial Final Data in Q4 2024
Comments
$Capricor Therapeutics(CAPR.US$
Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy with an Aim to Expedite BLA Pathway
Capricor Therapeutics (NASDAQ: CAPR) announced a successful Type-B meeting with the FDA for their lead asset, CAP-1002, aimed at treating Duchenne muscular dystrophy (DMD). The FDA approved a rolling Biologics License Application (BLA) submission, set to begin in Q3 2024. The rolling BLA process could stream...
Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy with an Aim to Expedite BLA Pathway
Capricor Therapeutics (NASDAQ: CAPR) announced a successful Type-B meeting with the FDA for their lead asset, CAP-1002, aimed at treating Duchenne muscular dystrophy (DMD). The FDA approved a rolling Biologics License Application (BLA) submission, set to begin in Q3 2024. The rolling BLA process could stream...
$Capricor Therapeutics(CAPR.US$ Capricor Therapeutics Inc - Remain on Track to Announce Topline Results From Phase 3 Hope-3 Pivotal Trial in Q4 of 2024
$Capricor Therapeutics(CAPR.US$ Reuters· just
Capricor Therapeutics Announces Positive 3-Year Efficacy Results From Hope-2 Open Label Extension Study of Cap-1002 in Duchenne Muscular Dystrophy
Capricor Therapeutics Announces Positive 3-Year Efficacy Results From Hope-2 Open Label Extension Study of Cap-1002 in Duchenne Muscular Dystrophy
2
$United Therapeutics(UTHR.US$ Phase 3
$Ironwood Pharmaceuticals(IRWD.US$ Phase 3
$Liquidia(LQDA.US$ Phase 3
$United Therapeutics(UTHR.US$ Phase 3
$MorphoSys(MOR.US$ Phase 3
$Immunocore(IMCR.US$ Phase 3
$Crinetics(CRNX.US$ Phase 3
$UroGen Pharma Ltd(URGN.US$ Phase 3
$AstraZeneca(AZN.US$ Phase 3
$AstraZeneca(AZN.US$ Phase 3
$AstraZeneca(AZN.US$ Phase 3
$AstraZeneca(AZN.US$ Phase 3
$Capricor Therapeutics(CAPR.US$ Phase 3
$Annexon(ANNX.US$ Phase 3
$Lipocine(LPCN.US$ Phase 3 ...
$Ironwood Pharmaceuticals(IRWD.US$ Phase 3
$Liquidia(LQDA.US$ Phase 3
$United Therapeutics(UTHR.US$ Phase 3
$MorphoSys(MOR.US$ Phase 3
$Immunocore(IMCR.US$ Phase 3
$Crinetics(CRNX.US$ Phase 3
$UroGen Pharma Ltd(URGN.US$ Phase 3
$AstraZeneca(AZN.US$ Phase 3
$AstraZeneca(AZN.US$ Phase 3
$AstraZeneca(AZN.US$ Phase 3
$AstraZeneca(AZN.US$ Phase 3
$Capricor Therapeutics(CAPR.US$ Phase 3
$Annexon(ANNX.US$ Phase 3
$Lipocine(LPCN.US$ Phase 3 ...
12
1
$Capricor Therapeutics(CAPR.US$ Capricor Therapeutics Announces Positive Type-B Meeting With FDA for Cap-1002 Program for Duchenne Muscular Dystrophy
1
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg